These data indicate that, in p53-positive prostate cancer cells, targeting locally expressed GnRH receptors by means of GnRH agonists sensitizes and resensitizes cancer cells to chemotherapy, in a p53-dependent manner. This evidence concerns the gene GNRHR and prostate carcinoma.